Main menu
Edison Group
  • Home
  • Equities

    Equities

    View All Equities

    Equities by Sector

    VolitionRx

    MCap

    USD76m

    Last close

    USD0.81

    ▲ 0.14 (20.90%)

    Canyon Resources

    MCap

    AUD262m

    Last close

    AUD0.19

    ▲ 0.02 (12.12%)

    Immix Biopharma

    MCap

    USD51m

    Last close

    USD1.82

    ▲ 0.12 (7.06%)

  • Sectors

    Sectors

  • Thematics

    Thematics

    View All Thematics

    Latest

  • Audiovisual

    Audiovisual

    View All Audiovisual

    Latest

OTC Markets Group (US: OTCM)

Last close As at 21/11/2024

55.78

▲ 0.74 (1.34%)

Market capitalisation

661m

Edison Investment Research is terminating coverage on OTC Markets Group. Please note you should no longer rely on any previous research or estimates for this company. All forecasts should now be considered redundant.

Previously published reports can still be accessed via our website.

Latest Insights

View More

Financials | Update

OTC Markets Group — Q122 – net income up 11%, but costs start to bite

Financials | Outlook

OTC Markets Group — Q421 was another beat, 2022 is more uncertain

Financials | Update

OTC Markets Group — Hitting it out of the ballpark

Financials | Update

OTC Markets Group — Revenue beat, positive business mix
Visit Website

Sector

Financials

Balance Sheet

Forecast net debt (US$m)

33.2

Forecast gearing ratio (%)

125

Share Price Performance

Financials

OTC Markets Group’s (OTCM’s) Q122 net income was up 11% y-o-y despite weaker financial markets trading volume and prices. Corporate services (+51% y-o-y) and market data licensing (+9% y-o-y) revenue was as resilient as expected and compensated for the 47% decline in OTC Link revenue. However, operating expenses rose by 12% due to rising staff compensation and IT. OTCM purchased Blue Sky Data for $12m cash in May 2022, allowing OTCM to improve its value proposition and expand its subscriber base. We maintain our assumption that markets will remain choppy due to concerns about inflation and rising interest rates. We have cut our EPS forecasts for FY22 and FY23 by 19% and 17% respectively to reflect higher operating expense assumptions. We have cut our dividend forecasts by 20% but note that this could be conservative given OTCM’s strong balance sheet and cash flow generation.

edison tv

Financials

Executive interview – OTC Markets at EKF 2019

edison tv

Financials

Executive interview – OTC Markets Group

Outlook

Financials

OTC Markets Group — Revenue progress across group

QuickView

Financials

OTC Markets Group — Gaining recognition of its premium markets

Update

Financials

OTC Markets Group — A year of investment for the future

Update

Financials

OTC Markets Group — Investing for future growth

Update

Financials

OTC Markets Group — Revenue, profit and regulatory recognition increase

Outlook

Financials

OTC Markets Group — Gaining domestic and international traction

Update

Financials

OTC Markets Group — Progress continues

Update

Financials

OTC Markets Group — Building the base for long-term growth

Update

Financials

OTC Markets Group — Clear focus on longer-term aims

Update

Financials

OTC Markets Group — Growing revenues and investing for the future

Outlook

Financials

OTC Markets Group — Acceleration in corporate client signings

research

Financials

OTC Markets Group — Growing market recognition

Update

Financials

OTC Markets Group — Update 22 November 2016

Update

Financials

OTC Markets Group — Update 21 November 2016

Update

Financials

OTC Markets Group — Update 6 September 2016

Update

Financials

OTC Markets Group — Update 13 May 2016

Outlook

Financials

OTC Markets Group — Update 19 April 2016

Update

Financials

OTC Markets Group — Update 19 November 2015